Optimizing Targeted Therapy in IgVH-Unmutated CLL

Video

Optimizing Targeted Therapy in IgVH-Unmutated CLL

A 58-Year Old Female with IgVH-Unmutetd CLL

  • A 58-year-old female with incidentally noted lymphocytosis on routine
  • PMH: hypercholesterolemia managed on simvistatin, mild osteoarthritis
  • PE: 1.0-cm cervical node, no palpable spleen or liver
  • PS, ECOG 0
  • Laboratory findings:
    • WBC; 45 X 109/L, 85% lymphocytes
    • Lymphocytes; 86.2 X 109/L
    • Hb; 13.9 g/dL
    • Platelets; 274 X 109/L
    • ANC; 1,950/mm3
    • LDH 160 U/L
  • Flow cytometry; CD5+, CD19+, CD20+(dim), CD23+, slg+ (dim), ZAP70+
  • Cytogenetics by FISH; del(17p), trisomy 12, IgVH unmutated
  • β2M, 3.6 mg/L
  • BM biopsy; 70% lymphocytes, diffuse pattern
  • Diagnosis; chronic lymphocytic leukemia
  • Observed for over 2 years, then developed progressive sever fatigue and night sweats
  • The patient was treated with ibrutinib and achieved a complete response to therapy after 2 months
Related Videos
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Prithviraj Bose, MD, an expert on myelofibrosis
Prithviraj Bose, MD, an expert on myelofibrosis
Related Content
Real-World Analysis Shows Promising Outcomes, Safety With Ibrutinib in CLL

Real-World Analysis Shows Promising Outcomes, Safety With Ibrutinib in CLL

April 20th 2024
Article

A 2-year follow-up study showed that ibrutinib maintained efficacy and safety among patients with chronic lymphocytic leukemia, highlighting its importance in the field. 

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL

Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL

April 10th 2024
Article

In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Examining Efficacy, Toxicity, and Cost-Effectiveness of Myeloma Therapies

Examining Efficacy, Toxicity, and Cost-Effectiveness of Myeloma Therapies

April 1st 2024
Article

In an interview with Targeted Oncology, Doris Hansen, MD, delved into the background, methods, design, and results from 3 recent myeloma studies.

Read More

Venetoclax Monotherapy Shows Deep, Durable Responses in R/R CLL

Venetoclax Monotherapy Shows Deep, Durable Responses in R/R CLL

March 22nd 2024
Article

Treatment with venetoclax appeared to improve responses in patients with relapsed or refractory chronic lymphocytic leukemia, according to findings from a phase 3b study.

Read More